AFM24
2 products
4 abstracts
1 target
Target
EGFR mutationAbstract
Preliminary results from the phase 2 study of AFM24 in combination with atezolizumab in patients with EGFR wild-type (EGFR-WT) non-small cell lung cancer (NSCLC).Org: Janusz Korczak Provincial Specialist Hopsital, Institute of Cancer Research at the Royal Marsden, Phase 1 Clinical Trial Unit, NEXT Oncology, Hospital Universitario Quirón Salud, Early Phase Clinial Trials Unit, Maria Sklodowska-Curie National Research Institute of Oncology,
Abstract
Leveraging innate immunity with AFM24, a novel CD16A and epidermal growth factor receptor (EGFR) bispecific innate cell engager: Interim results for the non-small cell lung cancer (NSCLC) cohort.Org: Affimed Inc., Samsung Medical Center, INCLIVA, Biomedical Research Institute, Vall d'Hebron Institute of Oncology, Affimed,
Abstract
Investigating the novel CD16A and epidermal growth factor receptor (EGFR) bispecific innate cell engager, AFM24, to leverage the innate immune system: Interim results from the colorectal cancer (CRC) cohort.Org: INCLIVA-Biomedical Research Institute, Biomedical Research Institute INCLIVA, Hospital Clínico Universitario-INCLIVIA, Valencia, Spain, University of Valencia, Affimed Inc.,
Product
AFM24 + AtezolizumabProduct
AFM24